Featured Publications
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effectsRelationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study
Patel KM, Shafiq M, Malik AA, Cobanoglu A, Klotz M, Eric Humphries J, Lee A, Murray T, Wilkinson D, Yildirim I, Elharake JA, Diaz R, Rojas R, Kuperwajs Cohen A, Omer SB, Gilliam WS. Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study. Vaccine 2022, 40: 4098-4104. PMID: 35660329, PMCID: PMC9135692, DOI: 10.1016/j.vaccine.2022.05.064.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationProspective cohort studyCare providersNonpharmaceutical interventionsChild care providersCohort studyLikelihood of vaccinationPreventative health behaviorsVaccinationHealth behaviorsCare programMandatory vaccinationSignificant associationVaccine mandatesDistrict of ColumbiaLarge healthInterventionPandemic controlCOVID-19Child care programsProvidersEmail surveyNonadherenceMeasures
2022
The Impact of Testing Capacity and Compliance With Isolation on COVID-19: A Mathematical Modeling Study
Yu Z, Keskinocak P, Steimle L, Yildirim I. The Impact of Testing Capacity and Compliance With Isolation on COVID-19: A Mathematical Modeling Study. AJPM Focus 2022, 1: 100006. PMID: 36942015, PMCID: PMC9119710, DOI: 10.1016/j.focus.2022.100006.Peer-Reviewed Original ResearchTesting capacityCOVID-19Infection attack rateInfectious respiratory diseaseFuture pandemicsAdditional testing capacityEarly startLow testing capacityRespiratory diseaseBenefits of testingDiagnostic testingAbsence of testingDiagnostic testsAttack rateDays of delayHigh compliancePublic healthInfection spreadDiseaseStart of testingSignificant benefitsPandemicComplianceMathematical modeling studiesPotential benefitsThe balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants
Kim D, Keskinocak P, Pekgün P, Yildirim İ. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. Scientific Reports 2022, 12: 7493. PMID: 35523832, PMCID: PMC9075929, DOI: 10.1038/s41598-022-11060-8.Peer-Reviewed Original ResearchConceptsOverall public health impactInfection attack rateCOVID-19 vaccineSARS-CoV-2Public health impactVaccine effectivenessAdverse outcomesMultiple vaccinesInitial efficacySuccessful immunization strategyImmunization strategiesVaccineLow-income countriesAttack rateEfficacyCOVID-19COVID-19 pandemicHealth impactsInfection spreadRecovered-deceased [SI(Q/F)RD] modelEfficacy levelsPandemicHospitalizationVaccinationVariantsAssociation of Child Masking With COVID-19–Related Closures in US Childcare Programs
Murray TS, Malik AA, Shafiq M, Lee A, Harris C, Klotz M, Humphries JE, Patel KM, Wilkinson D, Yildirim I, Elharake JA, Diaz R, Reyes C, Omer SB, Gilliam WS. Association of Child Masking With COVID-19–Related Closures in US Childcare Programs. JAMA Network Open 2022, 5: e2141227. PMID: 35084484, PMCID: PMC8796014, DOI: 10.1001/jamanetworkopen.2021.41227.Peer-Reviewed Original ResearchConceptsCOVID-19 casesLower riskImportant public health policy implicationsCOVID-19-related closuresPublic health policy implicationsChildren 2 yearsElectronic survey studyCenter-based childcare programsHealth policy implicationsSARS-CoV-2Survey studyChildcare professionalsMAIN OUTCOMEProgram closureHealth policyStudy periodRobust SEsBaselineChildcare programsCOVID-19Young childrenChildcare settingsChildrenPhysical distancingAssociation
2021
Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach
Kim D, Pekgün P, Yildirim İ, Keskinocak P. Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach. Vaccine 2021, 39: 6876-6882. PMID: 34688498, PMCID: PMC8520874, DOI: 10.1016/j.vaccine.2021.10.025.Peer-Reviewed Original ResearchConceptsInfection attack rateVaccine typesDifferent vaccine typesResource-limited countriesHigh-efficacy vaccinesDifferent study parametersVaccine shortageEfficacy vaccineHealth outcomesLife-saving vaccinesVaccineVaccine distributionLow efficacyAttack rateStudy parametersEfficacyHigh efficacyCOVID-19COVID-19 pandemicDeceased (SIRD) modelDifferent resource allocation decisionsLimited accessDelayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1178-1186. PMID: 33953384, PMCID: PMC8785364, DOI: 10.1038/s41591-021-01355-0.Peer-Reviewed Original ResearchConceptsDeceased patientsAntibody levelsAntibody responseDisease severityAnti-S IgG levelsCOVID-19 disease outcomesFatal COVID-19Impaired viral controlWorse clinical progressionWorse disease severitySevere COVID-19Length of hospitalizationImmunoglobulin G levelsHumoral immune responseCoronavirus disease 2019COVID-19 mortalityCOVID-19Domain (RBD) IgGSeroconversion kineticsDisease courseIgG levelsClinical parametersClinical progressionHumoral responseDisease onset
2020
The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19
McAteer J, Yildirim I, Chahroudi A. The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19. Clinical Infectious Diseases 2020, 71: 703-705. PMID: 32282038, PMCID: PMC7184475, DOI: 10.1093/cid/ciaa433.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Vaccines actCoronavirus 2Clinical trialsVaccine hesitancyVaccine candidatesNovel vaccinesCOVID-19COVID-19 pandemicVaccineTimes of COVID19PandemicTrials